The Effects of Neuromonitoring and Cerebrolysin Administration on Outcomes in Patients with Traumatic Brain Injury-An Interventional Pilot Study.

Jarosz K, Kojder K, Skonieczna-Żydecka K, Andrzejewska A, Sołek-Pastuszka J, Jurczak A

Journal of clinical medicine8 Jan 2024Cited by 2 (Europe PMC)

PMID38256487PMCIDPMC10816546DOI10.3390/jcm13020353PepBankPUB-38256487

Summary

IntroductionTraumatic brain injury (TBI) is one of the most common causes of death and an important burden to the worldwide healthcare system and society. There is a lack of guidelines for types of monitoring or neuroprotective therapy. The aim of this pilot study was to assess its feasibility and, furthermore, to evaluate the impact of Cerebrolysin on the following clinical outcomes: length of stay, Glasgow Outcome Scale (GOS) and mortality.MethodsA cohort of 56 patients was included in this non-randomised, real-time, pre-post-interventional study. The patients were assessed with the Glasgow Coma Scale (GCS) and divided into two groups: severe (GCS 8). After the radiological examination (CT scan), the patients were qualified for an immediate neurosurgical procedure if needed. The patients were admitted to the intensive care unit, where a standardised protocol for TBI treatment was implemented. Additional neuromonitoring was applied.ResultsThere were 56 patients (19 females; 33.9%), of which 41 were considered severe cases; the patients were allocated to the Cerebrolysin (n = 25) or control groups (n = 31). In a generalised linear model (GLM) approach, the use of Cerebrolysin was associated with a decrease in the probability of death in non-severe patients (by 0.333 (standard error (SE) = 0.157, p = 0.034)) but not in severe patients (estimate (Est.) = -0.115, SE = 0.127, p = 0.364). Patients who received Cerebrolysin and who were neuromonitored had favourable outcomes and better survival rates.ConclusionsA multimodal treatment approach with monitoring and Cerebrolysin may have a beneficial effect on patients with less severe TBIs; however, the present study has multiple limitations, and further research is needed.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

2 results from studies that gave the peptide. 2 results from people.

01HumanNon-randomized trialEfficacy outcome
In severe TBI patients, Cerebrolysin use was not associated with a significant decrease in death probability versus controls.
In plain wordsIn severe brain injury patients, Cerebrolysin use was not linked to a significant decrease in death probability versus controls.
Peptide
Cerebrolysin
Outcome
No significant changeDeath probability in severe TBI
Study
n = 41
Comparator
Control group
Outcome group
Mortality · Nervous system and cognition
Studied dose
Dose not stated
Measurements
Estimate
−0.115
severe TBI
Standard error
0.127
severe TBI
P value
0.364
severe TBI
Source sentences
Summary
but not in severe patients (estimate (Est.) = -0.115, SE = 0.127, p = 0.364).
3 context sentences(design, population, supporting numbers)
Summary · context
A cohort of 56 patients was included in this non-randomised, real-time, pre-post-interventional study.
Summary · context
The patients were assessed with the Glasgow Coma Scale (GCS) and divided into two groups: severe (GCS 8).
Summary · context
There were 56 patients (19 females; 33.9%), of which 41 were considered severe cases; the patients were allocated to the Cerebrolysin (n = 25) or control groups (n = 31).
Show in the study text Report a problemFND-3825648702
02HumanNon-randomized trialEfficacy outcome
In non-severe TBI patients, Cerebrolysin use was associated with lower death probability than controls.
In plain wordsIn non-severe brain injury patients, Cerebrolysin use was linked to lower death probability than controls.
Peptide
Cerebrolysin
Outcome
DecreaseDeath probability in non-severe TBI
Study
n: not reported in source
Comparator
Control group
Outcome group
Mortality · Nervous system and cognition
Studied dose
Dose not stated
Measurements
Death probability decrease
0.333
non-severe TBI
Standard error
0.157
non-severe TBI
P value
0.034
non-severe TBI
Source sentences
Summary
In a generalised linear model (GLM) approach, the use of Cerebrolysin was associated with a decrease in the probability of death in non-severe patients (by 0.333 (standard error (SE) = 0.157, p = 0.034))
2 context sentences(design, population, supporting numbers)
Summary · context
A cohort of 56 patients was included in this non-randomised, real-time, pre-post-interventional study.
Summary · context
The patients were assessed with the Glasgow Coma Scale (GCS) and divided into two groups: severe (GCS 8).
Show in the study text Report a problemFND-3825648701

Studies that did not test the peptide alone1

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

03HumanNot a test of Cerebrolysin aloneNon-randomized trialEfficacy outcome
In TBI patients, Cerebrolysin with neuromonitoring was associated with better survival rates.
In plain wordsIn brain injury patients, Cerebrolysin with neuromonitoring was linked to better survival rates.
Peptide
Cerebrolysin
Outcome
IncreaseSurvival with neuromonitoring
Study
n: not reported in source
Outcome group
Mortality · Nervous system and cognition
Source sentences
Summary
Patients who received Cerebrolysin and who were neuromonitored had favourable outcomes and better survival rates.
2 context sentences(design, population, supporting numbers)
Summary · context
A cohort of 56 patients was included in this non-randomised, real-time, pre-post-interventional study.
Summary · context
The patients were assessed with the Glasgow Coma Scale (GCS) and divided into two groups: severe (GCS 8).
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Show in the study text Report a problemFND-3825648704

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.